EANS-News: november Aktiengesellschaft / November AG subsidiary PROGEN signs exclusive distribution agreement with Asuragen

New: KRAS/BRAF Test for Luminex-User

New: AmplideX FMR1 PCR-Assay

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Research & Development/Distribution

Subtitle: New: KRAS/BRAF Test for Luminex-User
New: AmplideX FMR1 PCR-Assay

Cologne (euro adhoc) - PROGEN Biotechnik GmbH, a daughter of the
November AG, has signed an exclusive distribution contract for
Germany with the U.S.A. based Asuragen Inc., a company focused on
personalized medicine and companion diagnostics in the field of
oncology and human genetics.

PROGEN is now in a position to further expand its product line of
multiplexed assays enabling the detection of mutations often found in
solid tumors, such as KRAS or BRAF, and fusion transcripts or
mutations associated with specific leukemia types or subtypes. These
assays incorporate Signature® technology which is optimized for the
rapid multiplex analysis of nucleic acid sequences in a single
reaction, thus enhancing operational efficiencies through reduced
costs and streamlined workflow. The signature® reagents are adapted
for use on the Luminex® platform.

Additionally, PROGEN offers now two state-of-the-art PCR
technologies, developed by Asuragen, for molecular characterization
of the trinucleotide repeat in the 5´ region of the fragile X mental
retardation (FMR1) gene for routine screening testing. The highly
sensitive and time-saving assay is suited for the detection of FMR1
mutations in pre- and postnatal diagnosis and allows initiating early
measures for improvement of the living conditions of the patients.

PROGEN is thereby extending its product line of biomarker/molecular
diagnostics, and Luminex®-based tests for further assays. Thus, the
company is consequently pursuing its strategy to offer a broad
portfolio of own developed tests as well as products from other
manufacturers.

About Luminex® Technology The xMAP® (Multi Analyte Profiling)
technology developed by Luminex® (www.luminexcorp.com) is an
innovative assay platform for a large range of applications. With
this technology it is possible to simultaneously test 100 parameters
in one test run. Thus, the user saves time and sample material. The
technology is based on microscopically small polystyrene beads which
are coated with antigens e.g. against different infectious diseases.
The automated process allows the beads to identify up to 100
different analytes from one sample. This very sensitive and specific
detection enables fast screening tests of many different samples as
well as a differential sample analysis.

About november AG / PROGEN Biotechnik GmbH november AG, Koeln
(www.november.de) is an investment and holding company, listed in the
prime standard of the regulated market of the German stock exchange
(Deutsche Börse), with special focus on medical technology,
biotechnology, and environmental technologies and 100% shareholder of
PROGEN Biotechnik GmbH. PROGEN Biotechnik GmbH, Heidelberg
(www.progen.de), is manufacturer of in vitro diagnostics (borrelia,
hanta virus, FSME) and research reagents (antibodies, polypeptides,
AAV, hyperphage, www.hyperphage.com), certified to DIN EN ISO
13485:2007, as well as for the production of multiplex assays for the
Luminex® platform. PROGEN is member of the VDGH (German Association
of Diagnostic Manufacturers).

About Asuragen Inc. Asuragen Inc., Austin, USA, (www.asuragen.com) is
a fully integrated molecular diagnostic company focused on
personalized medicine and companion diagnostics, with emphasis on
mRNA/miRNA applications in oncology. As an FDA-registered medical
device manufacturer Asuragen offers cGMP development and
manufacturing capabilities available for contract manufacture with a
special focus on in vitro transcribed RNA. Asuragen has become a
leader in companion diagnostics by discovering and developing
predictive and prognostic test for its pharmaceutical and
biotechnology partners.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: november Aktiengesellschaft
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Dirk Zurek

CEO

Tel.: +49 (0) 221 82200 520 10

E-Mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade